{"filing":{"accession_number":"0001193125-26-263873","cik":"0001812364","ticker":"RLAY","company_name":"Relay Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-09","report_date":null,"primary_document":"rlay-20260609.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1812364/000119312526263873/rlay-20260609.htm"},"events":[{"id":5931,"run_id":5204,"accession_number":"0001193125-26-263873","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Relay Therapeutics held its 2026 Annual Meeting of Stockholders, at which shareholders voted on and approved four proposals: election of class III directors Douglas S. Ingram and Claire Mazumdar, Ph.D.; a non-binding advisory vote on executive compensation; ratification of Ernst \u0026 Young LLP as independent auditor; and approval of an amendment to the Certificate of Incorporation increasing authorized common shares from 300 million to 450 million. All proposals passed with substantial majorities.","company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","filing_date":"2026-06-09","form":"8-K","submitted_at":null,"items":[{"id":5598,"accession_number":"0001193125-26-263873","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The filing discloses an amendment to the Certificate of Incorporation increasing authorized common shares from 300 million to 450 million, approved by stockholders at the 2026 Annual Meeting. While this is a structural corporate action that could signal intent to issue additional equity (potentially dilutive), the disclosure itself is primarily administrative—a routine charter amendment. The materiality lies in the potential for future dilution rather than an immediate material event. This does not fit cleanly into the specific event categories (not a dilutive issuance itself, not a shareholder vote result per se, though voting occurred), so \"other_material\" is most appropriate.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:37:26.731234+00:00","company_name":"","ticker":null,"filing_date":""},{"id":5599,"accession_number":"0001193125-26-263873","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder meeting results. The filing reports voting outcomes on four proposals: election of class III directors (Douglas S. Ingram and Claire Mazumdar, Ph.D.), non-binding advisory vote on executive compensation, ratification of Ernst \u0026 Young LLP as independent auditor, and approval of an amendment to increase authorized common shares from 300 million to 450 million. All proposals passed with substantial majorities, making this a material disclosure of governance and capital structure decisions approved by stockholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:37:26.731234+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5598,"accession_number":"0001193125-26-263873","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The filing discloses an amendment to the Certificate of Incorporation increasing authorized common shares from 300 million to 450 million, approved by stockholders at the 2026 Annual Meeting. While this is a structural corporate action that could signal intent to issue additional equity (potentially dilutive), the disclosure itself is primarily administrative—a routine charter amendment. The materiality lies in the potential for future dilution rather than an immediate material event. This does not fit cleanly into the specific event categories (not a dilutive issuance itself, not a shareholder vote result per se, though voting occurred), so \"other_material\" is most appropriate.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:37:26.731234+00:00","company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","filing_date":"2026-06-09"},{"id":5599,"accession_number":"0001193125-26-263873","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder meeting results. The filing reports voting outcomes on four proposals: election of class III directors (Douglas S. Ingram and Claire Mazumdar, Ph.D.), non-binding advisory vote on executive compensation, ratification of Ernst \u0026 Young LLP as independent auditor, and approval of an amendment to increase authorized common shares from 300 million to 450 million. All proposals passed with substantial majorities, making this a material disclosure of governance and capital structure decisions approved by stockholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:37:26.731234+00:00","company_name":"Relay Therapeutics, Inc.","ticker":"RLAY","filing_date":"2026-06-09"}]}